Paul Sax, MD
Enriched profileClinical Director of the Division of Infectious Diseases at Brigham and Women's Hospital · Brigham and Women's Hospital
Paul Sax is Clinical Director of the Division of Infectious Diseases at Brigham and Women's Hospital at Brigham and Women's Hospital. OpenAlex indexes 678 publications with 23,104 citations (h-index 74); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Infectious Disease profiles in the findmyKOL directory.
Data verified 23 Oct 2026
Overview
Updated 23 Oct 2026
Paul Sax, MD, is Clinical Director of the Division of Infectious Diseases at Brigham and Women's Hospital. The public record shows 678 publications with 23,104 citations (h-index 74), centered on HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, HIV Research and Treatment. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 8 companies, 1 NIH-funded awards (1994–2008).
- Most recent indexed publication: 2025 · Transplant infectious disease
- Top research focus: HIV/AIDS Research and Interventions
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 191.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Industry payments
Updated 23 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202522 payments$18,424openpaymentsdata.cms.gov ↗
- Shionogi IncProgram year20252 payments
- ViiV Healthcare CompanyProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
80.6%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor39.5%Tivicay59%Dovato41%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor16.8%Descovy82%Emtricitabine18%Part D<11 patients+ 5 more classes in this area
Cardiovascular
11.5%Statin5.1%Atorvastatin Calcium100%Part D<11 patientsCalcium channel blocker3.3%Amlodipine Besylate100%Part D<11 patients+ 1 more class in this area
Dermatology
4.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.8%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
1 NIH research award on record, funded 1994–2008 per NIH RePORTER. The latest:
- A5202: A PHASE III TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR
Brigham and Women'S Hospital
FY2008$4,810M01RR002635 - ALLRT: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS
Brigham and Women'S Hospital
FY2008$3,331M01RR002635 - HIV-1 DNA VRC-HIV 009-00 VP (GAG-POL-NEF_MULTICLADE ENV) IN HIV-1
Brigham and Women'S Hospital
FY2008$2,220M01RR002635
Congress activity
Updated 23 Oct 2026
1 congress contribution (2024) across ASH per OpenAlex. The most recent:
- Evolution of the Evidence for the Management of COVID-19 in Hematologic Malignancies: A Systematic Literature Review of Remdesivir
ASH Annual Meeting
ASH2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Social Media Savvy, It's More Than Just the #Hashtags: How the Use of Social Media in Transplant Infectious Diseases Can Impact the Field and Patients.
Transplant infectious disease
Article2025 - Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals.
Clinical infectious diseases
Article2024 - Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.
Clinical infectious diseases
Article2024 - Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy.
Journal of the American Heart Association
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of ViremiaArticle1,835 citations1997
- 02
- 03Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental FactorsArticle747 citations2020
- 04Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsArticle699 citations2018
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
blogs.nejm.org/hiv-id-observations/index.php/about-the-author
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →blogs.nejm.org ↗ - Other
massgeneralbrigham.org/en/doctors/s/paul-sax-3001918
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneralbrigham.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
- Board certified
Infectious Disease, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Board certified
Internal Medicine, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Editorial & leadership roles
journal and society appointments- Editor-in-Chief
Open Forum Infectious Diseases
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Editorial Board
NEJM Journal Watch Infectious Diseases
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Editorial advisory board
Medscape HIV/AIDS
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Section Editor
HIV/AIDS, UpToDate
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗ - Core faculty
International Antiviral Society – USA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →learn.hms.harvard.edu ↗ - Bruce and Robert Beal Distinguished Chair in Infectious Diseases
Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →learn.hms.harvard.edu ↗ - Associate Program Director
Mass General Brigham fellowship in Infectious Diseases
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneralbrigham.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clinician.nejm.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
Marc Sabatine, MD
Brigham and Women's Hospital
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital